NCT07502872

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Brown University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).

Conditions

• Diffuse Large B Cell Lymphoma
• High-grade B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell

Interventions

Type	Name	Description
DRUG	Tafasitamab	Cytolytic monoclonal antibody targeting CD19.
DRUG	Polatuzumab vedotin	CD79b-targeting antibody-drug conjugate
DRUG	Glofitamab	CD20xCD3 bispecific antibody
DRUG	Obinutuzumab	Anti-CD20 monoclonal antibody

Timeline

• Start date: 2026-05-01
• Primary completion: 2029-12-01
• Completion: 2029-12-01
• First posted: 2026-03-31
• Last updated: 2026-03-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study